胰高血糖素样肽1受体激动剂与钠-葡萄糖共转运蛋白2抑制剂与2型糖尿病患者肝硬化预防
在英國2型糖尿病患者中,采用活性对照新用药者队列设计,比较GLP-1RA与DPP-4抑制剂、SGLT-2抑制剂与DPP-4抑制剂。GLP-1RA与肝硬化风险无显著关联(HR 0.90,95%CI 0.68-1.19),SGLT-2抑制剂与肝硬化风险降低相关(HR 0.64,95%CI 0.46-0.90)。
要点
- 与DPP-4抑制剂相比,GLP-1RA未显著降低肝硬化风险(HR 0.90,95%CI 0.68-1.19)。
- 与DPP-4抑制剂相比,SGLT-2抑制剂与肝硬化风险降低相关(HR 0.64,95%CI 0.46-0.90)。
- SGLT-2抑制剂与失代偿期肝硬化风险降低相关(HR 0.74,95%CI 0.54-1.00)。
核心结论
- 在英国2型糖尿病患者中,与DPP-4抑制剂相比,GLP-1RA与肝硬化风险降低无显著关联。
- 与DPP-4抑制剂相比,SGLT-2抑制剂与肝硬化风险降低相关。
研究设计与样本
- 采用活性对照、新用药者方法的队列研究,使用英国临床实践研究数据链链接医院和国家统计数据库。
- 使用倾向评分精细分层加权的Cox比例风险模型计算风险比(HR)和95%CI。
- 第一队列比较25,516例起始GLP-1RA的患者与186,752例起始DPP-4抑制剂的患者。
- 第二队列比较33,161例起始SGLT-2抑制剂的患者与124,431例起始DPP-4抑制剂的患者。
主要发现
- GLP-1RA与DPP-4抑制剂相比,肝硬化发生率无显著关联(HR 0.90,95%CI 0.68-1.19),次要结局亦无显著关联。
- SGLT-2抑制剂与DPP-4抑制剂相比,肝硬化发生率降低相关(HR 0.64,95%CI 0.46-0.90)。
- SGLT-2抑制剂与DPP-4抑制剂相比,失代偿期肝硬化发生率降低相关(HR 0.74,95%CI 0.54-1.00)。
- SGLT-2抑制剂与DPP-4抑制剂相比,肝细胞癌风险和肝相关死亡风险未显示降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, separately, compared with dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with a reduced risk of cirrhosis and other adverse liver outcomes among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: With an active comparator, new-user approach, we conducted a cohort study using the U.K. Clinical Practice Research Datalink linked with hospital and national statistics databases. Cox proportional hazards models using propensity score fine stratification weighting were used to calculate hazard ratios (HRs) and 95% CIs for cirrhosis (primary outcome) and decompensated cirrhosis, hepatocellular carcinoma, and liver-related mortality (secondary outcomes). RESULTS: In the first cohort comparing 25,516 patients starting GLP-1RAs and 186,752 starting DPP-4 inhibitors, GLP-1RAs were not associated with the incidence of cirrhosis (HR 0.90, 95% CI 0.68-1.19) or the secondary outcomes. In a separate cohort comparing 33,161 patients starting SGLT-2 inhibitors and 124,431 starting DPP-4 inhibitors, SGLT-2 inhibitors were associated with a reduced incidence of cirrhosis (HR 0.64, 95% CI 0.46-0.90), as also decompensated cirrhosis (HR 0.74, 95% CI 0.54-1.00), but not with a lower risk of hepatocellular carcinoma or liver-related mortality. CONCLUSIONS: In patients with type 2 diabetes in the U.K., GLP-1RAs were not associated with a lower risk of cirrhosis compared with DPP-4 inhibitors in patients with type 2 diabetes. However, SGLT-2 inhibitors were associated with a lower risk of cirrhosis compared with DPP-4 inhibitors.
引用
- Pradhan R, Yin H, Lu S, et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care. 2025. PMID: 39774820. doi:10.2337/dc24-1903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。